CYRX - Company ID 0001124524
Cryoport, Inc. trades as CYRX. In its fiscal 2025 annual report the company posted revenue of $176.18M, up 12.4% from the prior year and net income of $78.30M. This page tracks Cryoport, Inc. through 992 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
With latest filings
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Over the last 9 fiscal years Cryoport, Inc.'s revenue grew from $7.68M to $176.18M, a compound annual growth rate of 41.6%. Net profit margin expanded from -170.8% to 44.4% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| Quarterly report | 10-Q | 2026-05-05 |
| Major company event | 8-K | 2026-05-04 |
| Insider trade | 4 | 2026-04-23 |
| Annual report to shareholders | ARS | 2026-04-22 |
| Proxy materials | DEFA14A | 2026-04-22 |
| Proxy statement | DEF 14A | 2026-04-22 |
| Insider trade | 4 | 2026-04-08 |
| SCHEDULE 13G/A | - | 2026-03-26 |
The largest companies sharing Cryoport, Inc.'s SEC industry classification (pharmaceutical preparations).
Cryoport, Inc. reported revenue of $176.18M for fiscal year 2025, an increase of 12.4% year over year.
Yes. Cryoport, Inc. reported net income of $78.30M in its latest fiscal year.